| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC1002 |
| Trial ID | ChiCTR2200061341 |
| Disease | Pancreatic Cancer |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | KRAS TCR-T cells |
| HLA | HLA phenotype positive |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | An exploring clinical research on evaluating the safety, efficiency and pharmacokinetics of KRAS mutated antigen-specific TCR-T cell therapy for advanced pancreatic cancer and other solid tumors |
| Year | 2022 |
| Country | China |
| Company sponsor | Sun Yat-sen Memorial Hospital, Sun Yat-sen University |
| Cohort 1 | |||||||||
|
|||||||||